文献速递肾小球疾病

低剂量泼尼松龙联合活性维生素D治疗成人微小病变肾病:随机非劣效试验

A randomized controlled non-inferiority trial examined lower dose prednisolone and activated vitamin D in adult minimal change podocytopathy.
PubMed 文献 · Kidney Int · 2026-03-27

ADAPT试验纳入67例成人微小病变肾病(MCD),比较低剂量泼尼松龙联合阿法骨化醇与标准高剂量泼尼松龙。虽未达到统计非劣效,但两组缓解率、缓解时间及复发率相当,联合组累计泼尼松龙剂量更低、严重不良事件和糖皮质激素毒性更少。

要点

  • 低剂量联合阿法骨化醇未达非劣效,但缓解率与高剂量组相当。
  • 联合组累计泼尼松龙剂量显著更低(3.7 g vs 8.0 g)。
  • 联合组严重不良事件和糖皮质激素毒性更少。

核心结论

  • 低剂量泼尼松龙联合阿法骨化醇未达到非劣效,但疗效与高剂量泼尼松龙相当且更安全。

研究设计与样本

  • 随机、开放标签、非劣效、多中心试验,纳入67例成人微小病变肾病(MCD)患者。

主要发现

  • 低剂量联合组缓解率88%(95%CI 74-96),高剂量组91%(95%CI 78-98)。
  • 中位缓解时间分别为28天(IQR 14-54)和23天(IQR 13-47)。
  • 复发率分别为35%和32%,中位复发时间分别为195天(IQR 100-275)和179天(IQR 161-206)。
  • 累计泼尼松龙总剂量分别为3.7 g和8.0 g。
  • 严重不良事件更少,糖皮质激素相关毒性分别为46(IQR 11-77)和74(IQR 30-119),联合组显著更低。

临床怎么用

  • 对成人MCD,低剂量泼尼松龙联合阿法骨化醇可作为高剂量泼尼松龙的安全替代方案,疗效相似且毒性更少。

局限性

  • 统计非劣效未成立,需谨慎解读疗效相当的结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Minimal change disease (MCD) is a frequent cause of nephrotic syndrome in adults. Standard treatment consists of high-dose prednisolone (1 mg/kg/d), which induces remission in over 80% of patients but is associated with considerable glucocorticoid toxicity. Here, in the ADAPT trial, we investigated whether a lower dose of prednisolone combined with activated vitamin D (alfacalcidol) could be non-inferior to the standard high-dose regimen in achieving remission. METHODS: In this randomized, open-label, non-inferiority, multicenter trial, 67 adults with MCD were assigned to either lower-dose prednisolone with alfacalcidol or standard high-dose prednisolone. The primary endpoint was remission rate. Secondary endpoints included time to remission, relapse rate, time to relapse, incidence of serious adverse events and glucocorticoid-related toxicity. RESULTS: Although statistical non-inferiority was not established, rates, time to remission and relapse were comparable between groups. Remission was achieved in 88% (95% confidence interval: 74-96) of patients in the lower-dose prednisolone/alfacalcidol group and in 91% (78-98) of those receiving high-dose prednisolone. Median time to remission was 28 days [interquartile range 14-54] versus 23 days [13-47], respectively. Relapses occurred in 35% and 32% of patients, with median times to relapse of 195 days [100-275] and 179 days [161-206], respectively. The total cumulative doses of prednisolone were significantly less 3.7 g vs 8.0 g, respectively. The number of serious adverse events were less and glucocorticoid-related toxicities (46 [11-77] vs. 74 [30-119]) were significantly less in the lower-dose/ alfacalcidol group than the high-dose group, respectively. CONCLUSIONS: Non-inferiority was not reached for the combined intervention with lower dose prednisolone and alfacalcidol compared to standard prednisolone treatment. But the combined treatment offers a safer alternative to high-dose prednisolone for treatment of MCD, with similar efficacy but fewer serious adverse events and reduced glucocorticoid toxicity. TRIAL REGISTRATION: Registered at ClinicalTrials.gov with study number NCT03210688.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Kristensen T, Tougaard B, Thuesen AD, et al. A randomized controlled non-inferiority trial examined lower dose prednisolone and activated vitamin D in adult minimal change podocytopathy. Kidney Int. 2026. PMID: 41905593. doi:10.1016/j.kint.2026.02.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。